What is the Vertex Pharmaceuticals Inc. stock price forecast?

Vertex Pharmaceuticals Inc. is currently trading at $453.17. View real-time AI analysis on Alpha Lenz.

What is Vertex Pharmaceuticals Inc. insider trading activity?

View the latest insider trading data for Vertex Pharmaceuticals Inc. on Alpha Lenz.

What is Vertex Pharmaceuticals Inc.'s P/E ratio?

Vertex Pharmaceuticals Inc.'s P/E ratio is 29.3.

Vertex Pharmaceuticals Inc.

NASDAQ · VRTX

$453.17+2.71(+0.60%)Pre-market

Ask about Vertex Pharmaceuticals Inc.'s future dividend policy...

Alpha Chat Insight

“Vertex Pharmaceuticals Inc. trades at a P/E of 29.3 (premium valuation) with strong ROE of 22.5%. 3Y revenue CAGR of 10.4% highlights clear growth momentum.”

Ask for details →

Company Overview

Vertex Pharmaceuticals Inc. is a leading biotechnology company focused on the discovery, development, and commercialization of innovative therapies for serious diseases. Primarily, Vertex is known for its pioneering work in treating cystic fibrosis (CF), a genetic disorder that affects respiratory and digestive systems. Through its robust portfolio of CF-focused therapies, Vertex addresses a significant unmet medical need, improving the quality of life for patients worldwide. The company's research pipeline also includes promising treatments for other serious conditions, including sickle cell disease and beta thalassemia. Based in Boston, Massachusetts, Vertex Pharmaceuticals serves the global healthcare sector, collaborating with key industry players and academic institutions to advance its scientific initiatives. Its role in the biotechnology landscape is significant, both for its impact on patient outcomes and its contribution to advancing medical science through innovation and targeted therapeutic solutions.

CEODr. Reshma Kewalramani FASN, M.D.

Websitehttps://www.vrtx.com

SectorHealthcare

IndustryBiotechnology

Employees6,100

Company Statistics

FY 2025

Profile

$115.88BMarket Cap

$12.00BRevenue

0.00Shares Out

6,100Employees

Margins

86.24%Gross

43.72%EBITDA

37.95%Operating

38.69%Pre-Tax

32.94%Net

Valuation

29.31P/E

6.21P/B

9.66EV/Sales

21.50EV/EBITDA

36.28P/FCF

Growth (CAGR)

10.35%Rev 3Yr

14.10%Rev 5Yr

1.42%Op Inc 3Yr

9.68%Op Inc 5Yr

5.97%Net Inc 3Yr

7.83%Net Inc 5Yr

Returns

16.41%ROA

22.54%ROE

19.33%ROIC

Financial Health

$5.08BCash & Cash Equivalents

$1.89BNet Debt

37.38%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Vertex Pharmaceuticals Inc. trades at a P/E of 29.3 (premium valuation) with strong ROE of 22.5%. 3Y revenue CAGR of 10.4% highlights clear growth momentum.”

Ask for details →

Frequently Asked Questions

Vertex Pharmaceuticals Inc. (ticker: VRTX) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 6,100 employees. Market cap is $115.9B.

The current price is $453.17 with a P/E ratio of 29.31x and P/B of 6.21x.

ROE is 22.54% and operating margin is 37.95%. Annual revenue is $12.0B.